Early ctDNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naïve ALK-Positive Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer
J Thorac Oncol 2023 Jun 07;[EPub Ahead of Print], RA Soo, JF Martini, AJ van der Wekken, S Teraoka, R Ferrara, AT Shaw, D Shepard, AM Calella, A Polli, F Toffalorio, P Tomasini, CH Chiu, D Kowalski, HR Kim, BJ SolomonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.